Author: Buijze GA1, De Jong HMY2, Kox M3, van de Sande MG2, Van Schaardenburg D2,4, Van Vugt RM5, Popa CD6,7, Pickkers P3, Baeten DLP2
Affiliation: <sup>1</sup>Department of Orthopaedic Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
<sup>2</sup>Department of Rheumatology and Clinical Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands.
<sup>3</sup>Department of Intensive Care Medicine, Nijmegen Institute for Infection, Inflammation and Immunity, RadboudUMC Nijmegen, Nijmegen, The Netherlands.
<sup>4</sup>Reade, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands.
<sup>5</sup>Department of Rheumatology and Clinical Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
<sup>6</sup>Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.
<sup>7</sup>Department of Rheumatology, RadboudUMC Nijmegen, Nijmegen, The Netherlands.
Conference/Journal: PLoS One.
Date published: 2019 Dec 2
Other:
Volume ID: 14 , Issue ID: 12 , Pages: e0225749 , Special Notes: doi: 10.1371/journal.pone.0225749. eCollection 2019. , Word Count: 291
OBJECTIVES: The primary objective of this trial was to assess safety and anti-inflammatory effects of an add-on training program involving breathing exercises, cold exposure, and meditation in patients with axial spondyloarthritis.
METHODS: This study was an open-label, randomised, one-way crossover clinical proof-of-concept trial. Twenty-four patients with moderately active axial spondyloarthritis(ASDAS >2.1) and hs-CRP ≥5mg/L were included and randomised to an intervention (n = 13) and control group (n = 11) group that additionally received the intervention after the control period. The intervention period lasted for 8 weeks. The primary endpoint was safety, secondary endpoints were change in hs-CRP, serum calprotectin levels and ESR over the 8-week period. Exploratory endpoints included disease activity measured by ASDAS-CRP and BASDAI, quality of life (SF-36, EQ-5D, EQ-5D VAS), and hospital anxiety and depression (HADS).
RESULTS: We found no significant differences in adverse events between groups, with one serious adverse event occurring 8 weeks after end of the intervention and judged 'unrelated'. During the 8-week intervention period, there was a significant decline of ESR from (median [interquartile range] to 16 [9-26.5] to 9 [5-23] mm/hr, p = 0.040, whereas no effect was found in the control group (from 14 [8.3-27.3] to 16 [5-37] m/hr, p = 0.406). ASDAS-CRP declined from 3.1 [2.5-3.6] to 2.3 [1.9-3.2] in the intervention group (p = 0.044). A similar trend was observed for serum calprotectin (p = 0.064 in the intervention group versus p = 0.182 in the control group), but not for hs-CRP.
CONCLUSIONS: This proof-of-concept study in axial spondyloarthritis met its primary endpoint with no safety signals during the intervention. There was a significant decrease in ESR levels and ASDAS-CRP upon the add-on training program in the intervention group. These findings warrant full-scale randomised controlled trials of this novel therapeutic approach in patients with inflammatory conditions.
TRIAL REGISTRATION: ClinicalTrials.gov; NCT02744014.
PMID: 31790484 DOI: 10.1371/journal.pone.0225749